A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.

ABSTRACT:

Introduction

Various multigene predictors of breast cancer clinical outcome have been commercialized, but proved to be prognostic only for hormone receptor (HR) subsets overexpressing estrogen or progesterone receptors. Hormone receptor negative (HRneg) breast cancers, particularly those lacking HER2/ErbB2 overexpression and known as triple-negative (Tneg) cases, are heterogeneous and generally aggressive breast cancer subsets in need of prognostic subclassification, since most early stage HRneg and Tneg breast cancer patients are cured with conservative treatment yet invariably receive aggressive adjuvant chemotherapy.

Methods

An unbiased search for genes predictive of distant metastatic relapse was undertaken using a training cohort of 199 node-negative, adjuvant treatment

SUBMITTER: Yau C 

PROVIDER: S-EPMC3096978 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature